Childhood Solid TumorsPhase 1NCT02392793
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
A Phase 1 study testing Talazoparib, Irinotecan and Temozolomide in people with Childhood Solid Tumors, run by St. Jude Children's Research Hospital at 1 site in United States.
Trial summary
The drug, talazoparib, seems to work against cancer in test tubes and animals by preventing DNA repair in damaged cells leading to their death. Investigators do not know if talazoparib combined with irinotecan will work in humans. Read more about this study
- Who is it for?
- Ages 12 months to 25 years
- Conditions the study is for
- Childhood Solid Tumors
- What is being tested?
- Talazoparib, Irinotecan and Temozolomide
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 43 participants
- Where
- 1 siteUnited States
- Study dates
- 25 Mar 2015to 30 Aug 2019
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 months to 25 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Patients with refractory or recurrent solid tumors for which there is no standard therapy are eligible. Patients must have had histologic verification of malignancy at original diagnosis or at the time of relapse.
- 12 months - 25 years at the time of enrollment on study.
- Patients must have a BSA of ≥ 0.42 m^2 at the time of study enrollment due to capsule strength(s).
- Patients must have either measureable or evaluable disease.
- Life expectancy must be at least 8 weeks.
- Performance status: Karnofsky ≥ 50 for patients > 16 years of age; Lansky ≥ 50 for patients ≤ 16 years of age.
Show all 23Show fewer
- Prior therapy: Patients who have received prior therapy with an irinotecan-based or temozolomide-based regimen are eligible. Patients who have received prior therapy with a PARP inhibitor other than talazoparib are eligible; however, patients who have progressed on a PARP inhibitor plus irinotecan regimen are not eligible.
- Organ function: Must have adequate organ and bone marrow function as defined by the following parameters:
- Patients with solid tumors not metastatic to bone marrow:
- Peripheral absolute neutrophil count (ANC) ≥1,000/mm^3
- Platelet count ≥ 100,000/mm^3 (no transfusion within 7 days of enrollment)
- Hemoglobin ≥ 9 g/dL (with or without support)
- Patients with solid tumors metastatic to bone marrow will be eligible for study but not evaluable for hematologic toxicity. These patients must not be known to be refractory to red cell or platelet transfusions. At least 2 of every cohort of 3 patients must be evaluable for hematologic toxicity. If dose limiting hematologic toxicity is observed at any dose level, all subsequent patients enrolled must be evaluable for hematologic toxicity.
- Adequate renal function defined as: Serum creatinine concentration ≤3x the institutional upper limit of normal (ULN) or creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73m^2.
- Adequate liver function defined as: For Part A participants: normal liver function as defined by SGPT (ALT) concentration ≤5x the institutional ULN, a total bilirubin concentration ≤2x the institutional ULN for age, and serum albumin ≥ 2g/dL.
- Adequate liver function defined as: For Part B participants: normal liver function as defined by SGPT (ALT) concentration < 2.5 times institutional ULN, a total bilirubin concentration ≤ 1.5 times the institutional ULN for age, and serum albumin ≥ 2 g/dL.
- Patients must have fully recovered from the acute toxic effects of chemotherapy, immunotherapy, surgery, or radiotherapy prior to entering this study:
- Myelosuppressive chemotherapy: Patient has not received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea).
- Hematopoietic growth factors: At least 7 days must have elapsed since the completion of therapy with a growth factor. At least 14 days must have elapsed after receiving pegfilgrastim.
- Biologic (anti-neoplastic agent): At least 7 days must have elapsed since completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur.
- Monoclonal antibodies: At least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody.
- Radiotherapy: At least 2 weeks must have elapsed since any irradiation; at least 6 weeks must have elapsed since craniospinal RT or substantial bone marrow irradiation.
- All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent will be obtained, when appropriate, according to institutional guidelines.
Who cannot join
- Pregnant or breastfeeding.
- If sexually active and with childbearing potential, must agree to use effective method of contraception, such as intrauterine device, bilateral tubal ligation for ≥ 6 months before randomization, partner vasectomized for ≥ 6 months before randomization, and sexual abstinence when in relation to the preferred and usual lifestyle of the subject.
- Male subjects must use a condom when having sex with a pregnant woman and when having sex with a woman of childbearing potential from the time of the first dose of study drug through 105 days after the last dose of study drug.
- Contraception should be considered for a nonpregnant female partner of childbearing potential.
- Male subjects with partners of childbearing potential must use a condom and contraception should be considered for the female partner from the time of the first dose of study drug through 105 days after the last dose of study drug.
- Male subjects whose partners are pregnant should use condoms for the duration of the pregnancy.
Show all 20Show fewer
- Male and female subjects must agree not to donate sperm or eggs, respectively, from the first dose of study drug through 105 days and 45 days after the last dose of study drug, respectively (hormonal contraception is not allowed) prior to study entry, during treatment, and for 45 days after last dose of study drug.
- Females considered not of childbearing potential include those who are surgically sterile (bilateral salpingectomy, bilateral oophorectomy, or hysterectomy) or who are post menopausal, defined as: < 55 years of age with no spontaneous menses for ≥ 12 months before randomization and with a postmenopausal follicle stimulating hormone (FSH) concentration > 30 IU/L (or meeting criteria for post-menopausal status by the local laboratory).
- If females with childbearing potential, a negative serum pregnancy test at Screening and willing to have additional serum and urine pregnancy tests during the study
- Note: Females without childbearing potential include those in menopause ≥2 years, with tubal ligation ≥1 year before screening, or with total hysterectomy.
- Concomitant medications
- Corticosteroids: Patients receiving corticosteroids that have not been on a stable or decreasing dose for at least 7 days prior to enrollment are not eligible.
- Investigational drugs: Patients cannot receive other investigational drugs while on this study.
- Anti-GVHD drugs post-transplant: Patients receiving cyclosporine, tacrolimus or other GVHD agents are not eligible.
- Prior treatment with talazoparib.
- Unable to swallow capsules.
- Active, uncontrolled infection.
- Prior solid organ transplant.
- Prior total body irradiation (TBI).
- Unwilling or unable to comply with the safety monitoring requirements of this protocol.
Trial locations and contacts
1 site in 1 country.
United States1 site
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105
About this study
Official title: A Phase I Study of Talazoparib (BMN 673) Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
The drug, talazoparib, seems to work against cancer in test tubes and animals by preventing DNA repair in damaged cells leading to their death. Investigators do not know if talazoparib combined with irinotecan will work in humans. Talazoparib has been used in only a small number of adults and children, and there is much not yet known about it.
In Arm A of this study, investigators seek to find the safest dose of irinotecan to give with talazoparib to children and young adults. In a phase I study, different dose levels of drug may be tested. The first 2 or 3 patients will be given a dose, and if none of them has a bad side-effect, the next 2 or 3 patients will be given a higher dose. No temozolomide will be given in in Arm A.
Read more
The experimental drug combination of talazoparib and irinotecan will be tested in the hopes of finding a treatment that may be effective against recurrent or refractory solid tumors. The goals of study Arm A are:
- To determine whether the combination of talazoparib and irinotecan is a beneficial treatment for your cancer;
- To learn what kind of side effects talazoparib can cause;
- To learn what kind of side effects talazoparib in combination with irinotecan can cause;
- To learn more about the biology of talazoparib in children diagnosed with solid tumors.
The purpose of Arm B is to to find the safest doses of irinotecan and temozolomide to give with talazoparib to children and young adults with a solid malignancy.. Talazoparib belongs to a family of drugs called "poly ADP ribose polymerase or PARP inhibitors." Irinotecan and temozolomide belong to a family of drugs called "DNA damaging agents."
There are two arms of this trial, A and B. In this study, investigators hope that irinotecan (administered in Arm A) and irinotecan plus temozolomide (administered in Arm B) will damage the DNA of the cancer cells. Then, talazoparib (which is a PARP inhibitor) will block the repair of the cancer cell's damaged DNA, causing the cancer cell to die (a process called "apoptosis").
There are different types of cancers found in children and young adults which appear to be vulnerable to the combination of chemotherapy agents that will be given in this study. Work carried out in the lab show that these agents may be very promising in the treatment of ewing sarcoma, germ cell tumors, wilms tumor, medulloblastoma and possibly neuroblastoma.
Read the detailed description
In Arm A of this study, talazoparib will be administered orally on day 1 either once or twice per day depending on the dose level of the enrolled participant. Both oral talazoparib and intravenous (IV) irinotecan will then be administered daily, on days 2-6. Each cycle will last 21 days.
Once the maximum tolerated doses (MTDs) for talazoparib and irinotecan are determined, a second arm of the study (Arm B) will open administering talazoparib, irinotecan and temozolomide. Talazoparib will be given orally, on days 1-6. Intravenous irinotecan and oral temozolomide will be given on days 2-6. The study will estimate the maximum tolerated doses, describe the toxicities of therapy, estimate the response rate and characterize the pharmacokinetics of the combined talazoparib plus irinotecan with or without temozolomide.
This study is a traditional dose escalation study using a standard 3+3 phase I design. In Arm A, six or more dose levels will be evaluated for the combination of talazoparib and irinotecan. Once the MTDs of Arm A are determined, Arm B will open and evaluate the combination of talazoparib, irinotecan and temozolomide.
PRIMARY OBJECTIVES - ARM A
- To estimate the maximum tolerated doses (MTDs) of talazoparib (daily, days 1-6) combined with irinotecan (daily, days 2-6) given every 21 days in children with refractory or recurrent solid malignancies.
- To identify and describe the dose limiting toxicities of talazoparib and irinotecan administered in combination to patients with refractory or recurrent solid malignancies.
PRIMARY OBJECTIVES - ARM B
- To estimate the maximum tolerated dose (MTD) of temozolomide (given daily, days 2-6) when combined with talazoparib (daily, days 1-6) and irinotecan (daily, days 2-6) given every 21 days in children with refractory or recurrent solid malignancies.
- To identify and describe the dose limiting toxicities of temozolomide, talazoparib and irinotecan administered in combination to patients with refractory or recurrent solid malignancies.
SECONDARY OBJECTIVES
- To estimate the response rate, within the confines of a phase I study, to talazoparib plus irinotecan and talazoparib plus irinotecan and temozolomide administered in combination in pediatric patients with refractory or recurrent solid malignancies.
- To characterize the pharmacokinetics of talazoparib plus irinotecan and talazoparib plus irinotecan and temozolomide when given in combination to children with refractory or recurrent solid malignancies.
- Conditions
- Childhood Solid Tumors
- Being tested
- Talazoparib, Irinotecan, Temozolomide, Filgrastim, Peg-filgrastim
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TalazoparibDrug
Also called BMN 673
Given orally once or twice on day 1 (depending on the dose level), then daily on days 2-6.
IrinotecanDrug
Also called Camptosar®
Given intravenously daily, days 2-6 immediately following the talazoparib dose.
TemozolomideDrug
Also called Temodar
Given orally daily. Dose to be determined after MTD established with talazoparib plus irinotecan.
FilgrastimDrug
Also called G-CSF, Neupogen®
Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is >2,000/μL, unless peg-filgrastim is given.
Peg-filgrastimDrug
Also called Pegylated filgrastim, Neulasta®
Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is >2,000/μL, unless filgrastim is given.
| Study group | Role | What they receive |
|---|---|---|
| Arm A: Talazoparib Plus Irinotecan | Active comparator | Talazoparib will be administered orally on day 1 either once or twice per day depending on the dose level of the enrolled patient. Both oral talazoparib and IV irinotecan will then be administered daily, on days 2-6. Each cycle will last 21 days. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy.
Arm A is closed to enrollment. Receives: Drug: Talazoparib; Drug: Irinotecan; Drug: Filgrastim; Drug: Peg-filgrastim |
| Arm B: Talazoparib Plus Irinotecan Plus Temozolomide | Active comparator | Once the maximum tolerated doses (MTDs) for talazoparib and irinotecan are determined, a second arm of the study will open administering talazoparib, irinotecan and temozolomide. Talazoparib will be given orally, days 1-6. Intravenous irinotecan and oral temozolomide will be given days 2-6. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy. Receives: Drug: Talazoparib; Drug: Irinotecan; Drug: Temozolomide; Drug: Filgrastim; Drug: Peg-filgrastim |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maximum tolerated dose (MTD) of talazoparib combined with irinotecan
This study is a traditional dose escalation study using a standard 3+3 phase I design to define the MTD. Six or more dose levels will be evaluated for the combination of talazoparib and irinotecan. Each cycle will last 21 days with talazoparib given daily on days 1-6 and irinotecan given daily on days 2-6.
Measured: After first cycle (21 days) therapy of patients of Arm A.
Dose-limiting toxicities (DLT) of talazoparib combined with irinotecan
Dose-limiting toxicities defined in the first cycle of the combination of talazoparib and irinotecan will be summarized for patients treated at each dose level with DLTs type and grade.
Measured: After first cycle (21 days) therapy of patients of Arm A.
Maximum tolerated dose (MTD) of temozolomide combined with talazoparib
Once the MTD is defined for the combination of talazoparib plus irinotecan in Arm A, then temozolomide will be added to make a triple drug combination, talazoparib plus irinotecan and temozolomide. This is a traditional dose escalation study using a standard 3+3 phase I design to define the MTD. Six or more dose levels will be evaluated for the combination of talazoparib plus irinotecan and temozolomide. Each cycle will last 21 days with talazoparib given daily on days 1-6 and irinotecan and temozolomide given daily on days 2-6.
Measured: After first cycle (21 days) therapy of patients of Arm B.
Dose-limited toxicities (DLT) of combination therapy with temozolomide, talazoparib and irinotecan
DLT defined in the first cycle of the combination of talazoparib plus irinotecan and temozolomide will be summarized for patients treated at each dose level with DLTs type and grade.
Measured: After first cycle (21 days) therapy of patients of Arm B.
Secondary outcomes (11)
Response rate
We will provide summary statistics for the best overall response (complete response, partial response, stable disease and progressive disease) of patients experienced during treatment.
Measured: After 34 cycles of therapy (approximate 24 months).
Irinotecan Cmax
A population average value and variance will be reported for week 1 of course 1
Measured: days 1 and 5 (week 1) of course 1
Talazoparib Cmax
A population average value and variance will be reported for week 1 of course 1
Measured: days 1 and 5 (week 1) of course 1
Irinotecan AUC
A population average value and variance will be reported for week 1 of course 1
Measured: days 1 and 5 (week 1) of course 1
Talazoparib AUC
A population average value and variance will be reported for week 1 of course 1
Measured: days 1 and 5 (week 1) of course 1
Irinotecan Clearance
A population average value and variance will be reported for week 1 of course 1
Measured: days 1 and 5 (week 1) of course 1
Talazoparib Clearance
A population average value and variance will be reported for week 1 of course 1
Measured: days 1 and 5 (week 1) of course 1
Irinotecan Tmax
A population average value and variance will be reported for week 1 of course 1
Measured: days 1 and 5 (week 1) of course 1
Talazoparib Tmax
A population average value and variance will be reported for week 1 of course 1
Measured: days 1 and 5 (week 1) of course 1
Irinotecan t1/2
A population average value and variance will be reported for week 1 of course 1
Measured: days 1 and 5 (week 1) of course 1
Talazoparib t1/2
A population average value and variance will be reported for week 1 of course 1
Measured: days 1 and 5 (week 1) of course 1
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2015 (estimated)
- Study start25 Mar 2015
- Primary completion20 Feb 2019
- Study completion30 Aug 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Childhood Solid TumorsStudies of the same condition, open and under way.
- More trials run by St. Jude Children's Research HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 43 participants (actual)
Sponsor and investigators
- Lead sponsor
- St. Jude Children's Research Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- BioMarin Pharmaceutical, Alliance Pharma, Pfizer
- Responsible party
- Sponsor
- Investigators
- Sara M. Federico, MD, Principal investigator, St. Jude Children's Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02392793
- Sponsor's protocol ID
- BMNIRN
- Other IDs
- NCI-2015-00255
- Status last verified
- Feb 2021
- First submitted
- 6 Mar 2015
- Last updated
- 9 Feb 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I Study of Talazoparib (BMN 673) Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
- ClinicalTrials.gov ID
- NCT02392793
- Acronym / sponsor ID
- BMNIRN
- Conditions
- Childhood Solid Tumors
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 43 participants (actual)
- Lead sponsor
- St. Jude Children's Research HospitalUniversity, hospital or other
- Collaborators
- BioMarin Pharmaceutical, Alliance Pharma, Pfizer
- Study start
- 25 Mar 2015 (actual)
- Primary completion
- 20 Feb 2019 (actual)
- Study completion
- 30 Aug 2019 (actual)
- First posted
- 19 Mar 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The drug, talazoparib, seems to work against cancer in test tubes and animals by preventing DNA repair in damaged cells leading to their death. Investigators do not know if talazoparib combined with irinotecan will work in humans. Talazoparib has been used in only a small number of adults and children, and there is much not yet known about it.
In Arm A of this study, investigators seek to find the safest dose of irinotecan to give with talazoparib to children and young adults. In a phase I study, different dose levels of drug may be tested. The first 2 or 3 patients will be given a dose, and if none of them has a bad side-effect, the next 2 or 3 patients will be given a higher dose. No temozolomide will be given in in Arm A.
The experimental drug combination of talazoparib and irinotecan will be tested in the hopes of finding a treatment that may be effective against recurrent or refractory solid tumors. The goals of study Arm A are:
- To determine whether the combination of talazoparib and irinotecan is a beneficial treatment for your cancer;
- To learn what kind of side effects talazoparib can cause;
- To learn what kind of side effects talazoparib in combination with irinotecan can cause;
- To learn more about the biology of talazoparib in children diagnosed with solid tumors.
The purpose of Arm B is to to find the safest doses of irinotecan and temozolomide to give with talazoparib to children and young adults with a solid malignancy.. Talazoparib belongs to a family of drugs called "poly ADP ribose polymerase or PARP inhibitors." Irinotecan and temozolomide belong to a family of drugs called "DNA damaging agents."
There are two arms of this trial, A and B. In this study, investigators hope that irinotecan (administered in Arm A) and irinotecan plus temozolomide (administered in Arm B) will damage the DNA of the cancer cells. Then, talazoparib (which is a PARP inhibitor) will block the repair of the cancer cell's damaged DNA, causing the cancer cell to die (a process called "apoptosis").
There are different types of cancers found in children and young adults which appear to be vulnerable to the combination of chemotherapy agents that will be given in this study. Work carried out in the lab show that these agents may be very promising in the treatment of ewing sarcoma, germ cell tumors, wilms tumor, medulloblastoma and possibly neuroblastoma.
Detailed description
In Arm A of this study, talazoparib will be administered orally on day 1 either once or twice per day depending on the dose level of the enrolled participant. Both oral talazoparib and intravenous (IV) irinotecan will then be administered daily, on days 2-6. Each cycle will last 21 days.
Once the maximum tolerated doses (MTDs) for talazoparib and irinotecan are determined, a second arm of the study (Arm B) will open administering talazoparib, irinotecan and temozolomide. Talazoparib will be given orally, on days 1-6. Intravenous irinotecan and oral temozolomide will be given on days 2-6. The study will estimate the maximum tolerated doses, describe the toxicities of therapy, estimate the response rate and characterize the pharmacokinetics of the combined talazoparib plus irinotecan with or without temozolomide.
This study is a traditional dose escalation study using a standard 3+3 phase I design. In Arm A, six or more dose levels will be evaluated for the combination of talazoparib and irinotecan. Once the MTDs of Arm A are determined, Arm B will open and evaluate the combination of talazoparib, irinotecan and temozolomide.
PRIMARY OBJECTIVES - ARM A
- To estimate the maximum tolerated doses (MTDs) of talazoparib (daily, days 1-6) combined with irinotecan (daily, days 2-6) given every 21 days in children with refractory or recurrent solid malignancies.
- To identify and describe the dose limiting toxicities of talazoparib and irinotecan administered in combination to patients with refractory or recurrent solid malignancies.
PRIMARY OBJECTIVES - ARM B
- To estimate the maximum tolerated dose (MTD) of temozolomide (given daily, days 2-6) when combined with talazoparib (daily, days 1-6) and irinotecan (daily, days 2-6) given every 21 days in children with refractory or recurrent solid malignancies.
- To identify and describe the dose limiting toxicities of temozolomide, talazoparib and irinotecan administered in combination to patients with refractory or recurrent solid malignancies.
SECONDARY OBJECTIVES
- To estimate the response rate, within the confines of a phase I study, to talazoparib plus irinotecan and talazoparib plus irinotecan and temozolomide administered in combination in pediatric patients with refractory or recurrent solid malignancies.
- To characterize the pharmacokinetics of talazoparib plus irinotecan and talazoparib plus irinotecan and temozolomide when given in combination to children with refractory or recurrent solid malignancies.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm A: Talazoparib Plus Irinotecan | Active comparator | Drug: Talazoparib, Drug: Irinotecan, Drug: Filgrastim, Drug: Peg-filgrastimTalazoparib will be administered orally on day 1 either once or twice per day depending on the dose level of the enrolled patient. Both oral talazoparib and IV irinotecan will then be administered daily, on days 2-6. Each cycle will last 21 days. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy. Arm A is closed to enrollment. |
| Arm B: Talazoparib Plus Irinotecan Plus Temozolomide | Active comparator | Drug: Talazoparib, Drug: Irinotecan, Drug: Temozolomide, Drug: Filgrastim, Drug: Peg-filgrastimOnce the maximum tolerated doses (MTDs) for talazoparib and irinotecan are determined, a second arm of the study will open administering talazoparib, irinotecan and temozolomide. Talazoparib will be given orally, days 1-6. Intravenous irinotecan and oral temozolomide will be given days 2-6. Filgrastim or peg-filgrastim will be given following the last dose of chemotherapy. |
Who may qualify
- Ages
- 12 months to 25 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (23 listed)
- Patients with refractory or recurrent solid tumors for which there is no standard therapy are eligible. Patients must have had histologic verification of malignancy at original diagnosis or at the time of relapse.
- 12 months - 25 years at the time of enrollment on study.
- Patients must have a BSA of ≥ 0.42 m^2 at the time of study enrollment due to capsule strength(s).
- Patients must have either measureable or evaluable disease.
- Life expectancy must be at least 8 weeks.
Key exclusion criteria (20 listed)
- Pregnant or breastfeeding.
- Concomitant medications
- Prior treatment with talazoparib.
- Unable to swallow capsules.
- Active, uncontrolled infection.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TalazoparibAlso: BMN 673Given orally once or twice on day 1 (depending on the dose level), then daily on days 2-6. | Drug | Arm A: Talazoparib Plus Irinotecan, Arm B: Talazoparib Plus Irinotecan Plus Temozolomide |
| IrinotecanAlso: Camptosar®Given intravenously daily, days 2-6 immediately following the talazoparib dose. | Drug | Arm A: Talazoparib Plus Irinotecan, Arm B: Talazoparib Plus Irinotecan Plus Temozolomide |
| TemozolomideAlso: TemodarGiven orally daily. Dose to be determined after MTD established with talazoparib plus irinotecan. | Drug | Arm B: Talazoparib Plus Irinotecan Plus Temozolomide |
| FilgrastimAlso: G-CSF, Neupogen®Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is >2,000/μL, unless peg-filgrastim is given. | Drug | Arm A: Talazoparib Plus Irinotecan, Arm B: Talazoparib Plus Irinotecan Plus Temozolomide |
| Peg-filgrastimAlso: Pegylated filgrastim, Neulasta®Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is >2,000/μL, unless filgrastim is given. | Drug | Arm A: Talazoparib Plus Irinotecan, Arm B: Talazoparib Plus Irinotecan Plus Temozolomide |
Primary outcome
Maximum tolerated dose (MTD) of talazoparib combined with irinotecan
Time frame: After first cycle (21 days) therapy of patients of Arm A.
This study is a traditional dose escalation study using a standard 3+3 phase I design to define the MTD. Six or more dose levels will be evaluated for the combination of talazoparib and irinotecan. Each cycle will last 21 days with talazoparib given daily on days 1-6 and irinotecan given daily on days 2-6.
Dose-limiting toxicities (DLT) of talazoparib combined with irinotecan
Time frame: After first cycle (21 days) therapy of patients of Arm A.
Dose-limiting toxicities defined in the first cycle of the combination of talazoparib and irinotecan will be summarized for patients treated at each dose level with DLTs type and grade.
Maximum tolerated dose (MTD) of temozolomide combined with talazoparib
Time frame: After first cycle (21 days) therapy of patients of Arm B.
Once the MTD is defined for the combination of talazoparib plus irinotecan in Arm A, then temozolomide will be added to make a triple drug combination, talazoparib plus irinotecan and temozolomide. This is a traditional dose escalation study using a standard 3+3 phase I design to define the MTD. Six or more dose levels will be evaluated for the combination of talazoparib plus irinotecan and temozolomide. Each cycle will last 21 days with talazoparib given daily on days 1-6 and irinotecan and temozolomide given daily on days 2-6.
Dose-limited toxicities (DLT) of combination therapy with temozolomide, talazoparib and irinotecan
Time frame: After first cycle (21 days) therapy of patients of Arm B.
DLT defined in the first cycle of the combination of talazoparib plus irinotecan and temozolomide will be summarized for patients treated at each dose level with DLTs type and grade.
11 secondary outcomes
Response rate
Time frame: After 34 cycles of therapy (approximate 24 months).
Irinotecan Cmax
Time frame: days 1 and 5 (week 1) of course 1
Talazoparib Cmax
Time frame: days 1 and 5 (week 1) of course 1
Irinotecan AUC
Time frame: days 1 and 5 (week 1) of course 1
Talazoparib AUC
Time frame: days 1 and 5 (week 1) of course 1
Irinotecan Clearance
Time frame: days 1 and 5 (week 1) of course 1
Talazoparib Clearance
Time frame: days 1 and 5 (week 1) of course 1
Irinotecan Tmax
Time frame: days 1 and 5 (week 1) of course 1
Talazoparib Tmax
Time frame: days 1 and 5 (week 1) of course 1
Irinotecan t1/2
Time frame: days 1 and 5 (week 1) of course 1
Talazoparib t1/2
Time frame: days 1 and 5 (week 1) of course 1
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2021.
- St. Jude Children's Research HospitalLink provided by the sponsor.
- Clinical Trials Open at St. JudeLink provided by the sponsor.
Related trials for Childhood Solid Tumors
Recruiting
An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors
Solid Tumor, Adult, Solid Tumor, Childhood
RecruitingPhase 3
An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors
Childhood Malignant Solid Neoplasm, Childhood Malignant Thoracic Neoplasm
Active, not recruitingPhase 2
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Not yet recruitingPhase 1/2
A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat
Recurrent Childhood Ewing Sarcoma, Recurrent Childhood Malignant Solid Neoplasm
Not yet recruitingPhase 1/2
Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations
Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sara M. Federico, MD principal investigator
St. Jude Children's Research Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Talazoparib, Irinotecan and Temozolomide in people with Childhood Solid Tumors, run by St. Jude Children's Research Hospital at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 23 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 Feb 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maximum tolerated dose (MTD) of talazoparib combined with irinotecan (time frame: After first cycle (21 days) therapy of patients of Arm A.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2021; AzTrials last refreshed its copy on 7 Nov 2026.